Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus

Journal of Nuclear Medicine

Volumn 51, Issue 12, 2010, Pages 1863-1869

  Malik, Vinod ^a   Lucey, Julie A ^b   Duffy, George J ^b   Wilson, Lorraine ^b   McNamara, Leanne ^b   Keogan, Mary ^a   Gillham, Charles ^c   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b Blackrock Clinic Ireland   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

18F FDG PET; Chemoradiotherapy; Esophageal cancer; Response; Survival

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG UPTAKE; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL COUNT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; WHOLE BODY IMAGING; ADENOCARCINOMA; ADJUVANT THERAPY; COMPUTER ASSISTED DIAGNOSIS; ESOPHAGUS TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; SCINTISCANNING; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; SURVIVAL ANALYSIS; WHOLE BODY IMAGING;

EID: 78651325646     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.079566     Document Type: Article

References (29)

1. Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245:707-716.
2. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-2252.
3. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234.
4. Maher SG, Gillham CM, Duggan SP, et al. Gene expression analysis of diagnostic biopsies predicts pathologic regression to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg. 2009;250:729-737.
5. Stahl M, Stuscchke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-2317.
6. Bedenne L, Michael P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168.
7. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinoma of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
8. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the oesophagogastric junction. J Clin Oncol. 2006;24:4692-4698.
9. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
10. Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging. 2007;34:1925-1932.
11. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumour metabolic activity during chemoradiotherapy of oesophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908.
12. 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer. 2006;95:1174-1179.
13. 18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging. 2009;36:735-744.
14. 18F- fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894.
15. Bollschweiler E, Holscher AH. Prediction of tumour response by FDG-PET in patients with adenocarcinomas of the oesophagogastric junction. Eur J Nucl Med Mol Imaging. 2008;35:1742-1743.
16. Konski A, Doss M, Milestone B, et al. The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1123-1128.
17. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG-PET. Eur J Nucl Med Mol Imaging. 2004;31:1471-1478.
18. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
19. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 1994;73:2680-2686.
20. 18F-fluorodeoxyglucose positron emission tomography in the evaluation of therapy response assessment in lymphomas. Systematic literature review and meta-analysis. Rev Esp Med Nucl. 2009;28:48-55.
21. Hutchings M, Barrington S. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50(suppl 1):21S-30S.
22. 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J Nucl Med. 2009;50(suppl 1):89S-96S.
23. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential f-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445-7453.
24. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362-8370.
25. 18FFDG-PET in esophageal carcinoma. Eur J Surg Oncol. 2004;30:544-550.
26. Schiepers C, Haustermans K, Geboes K, Filez L, Bormans G, Penninckx F. The effect of preoperative radiation therapy on glucose utilization and cell kinetics in patients with primary rectal carcinoma. Cancer. 1999;85:803-811.
27. Haberkorn U, Morr I, Oberdorfer F, et al. Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine. J Nucl Med. 1994;35:1842-1850.
28. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
29. Hersh E, Wong V, Freireich E. Inhibition of the local inflammatory response in man by antimetabolites. Blood. 1966;27:38-48.